Randomised Evaluation of COVID-19 Therapy (RECOVERY)

Type: Interventional

Site and study lead:

  • Manchester Royal Infirmary: Prof Simon Carley
  • Wythenshawe Hospital: Dr Tim Felton
  • Royal Manchester Children’s Hospital: Dr Claire Murray

Patient group: all COVID-19 patients


  • Azithromycin
  • Convalscent Plasm
  • *Tocilizumab (secondary randomisation arm)

Funder: Medical Research Council

Sponsor: University of Oxford

More about RECOVERY

The purpose of this trial is to test if existing or new drugs can help patients hospitalised with confirmed COVID-19.

The therapies being tested will be evaluated to see if they are safe and effective when added to the usual standard of care.

RECOVERY has an ‘adaptive’ design, meaning it can test new therapies as they become available. The aim is for national data to be available to inform patient treatment within three months.